Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet
Số trang: 13
Loại file: pdf
Dung lượng: 2.52 MB
Lượt xem: 10
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Saroglitazar is a novel PPAR-α/γ agonist with predominant PPAR-α activity. In various preclinical models, saroglitazar has been shown to prevent & reverse symptoms of NASH. In view of these observations, and the fact that NASH is a progressive disease leading to HCC, we hypothesized that saroglitazar may prevent the development of HCC in rodents.
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Hepatocellular carcinoma Novel PPAR-α/γ agonist Reverse symptoms Nonalcoholic fatty liver diseaseTài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 175 0 0 -
6 trang 169 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 147 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 127 0 0 -
12 trang 98 0 0
-
19 trang 76 0 0
-
17 trang 68 0 0
-
9 trang 46 0 0
-
12 trang 40 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 40 0 0